News >

Ruxolitinib Combo Regimens Emerging in Myelofibrosis

Lisa Astor
Published: Tuesday, Sep 17, 2019

Naveen Pemmaraju, MD

Naveen Pemmaraju, MD

Although several newer JAK inhibitors are being investigated in myelofibrosis, such as pacritinib, momelotinib, and the recently FDA approved fedratinib (Inrebic), most combinations are being explored in combination with ruxolitinib (Jakafi), a JAK inhibitor that was approved for treating patients with intermediate or high-risk myelofibrosis in 2011.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication